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Introduction: Hypertension is an important risk factor for cardiovascular disease and its 
management requires improvement. New treatment strategies are needed.
Aims: This review analyses one of these strategies, which is the development of effective 
and safe combination therapy. Indeed, at least two antihypertensive agents are often needed to 
achieve blood pressure control. Exforge® (Novartis) is a new drug combination of the calcium 
channel blocker, amlodipine, and the angiotensin II receptor blocker, valsartan.
Evidence review: The amlodipine/valsartan combination is an association of two well-known 
antihypertensive products with specific targets in cardiovascular protection, namely calcium 
channel blockade and antagonism of the renin-angiotensin-aldosterone system. This kind of 
association, with neutral metabolic properties and significant antihypertensive efficacy, could 
be a useful new antihypertensive product. Currently available data have shown that this new 
combination is well-tolerated and effective even in severe hypertension.
Clinical value: Clinical trials are ongoing for further assessment of the efficacy, compliance, 
and safety of this combination and its congeners. No data exist to prove that the amlodipine/
valsartan combination is better than other antihypertensive strategies for cardiovascular or renal 
protection, but some trials with other combination therapies show such potential advantage.
Keywords: arterial hypertension, treatment, combination therapy, calcium channel blocker, 
amlodipine, angiotensin II receptor blocker, valsartan
Core evidence clinical impact summary for Exforge® (amlodipine/valsartan) in 
hypertension
Outcome measure Evidence Implications
Patient-oriented evidence
improvement in cardiovascular 
morbidity and mortality
 
Clear (for each 
agent alone)
 
Trials on both drugs as monotherapy have 
shown either direct protection against 
cardiovascular events or surrogate benefit 
by reducing blood pressure
Reduced atrial fibrillation Moderate Reduced recurrent atrial fibrillation
Patient acceptability Limited Low rate of adverse events
improvement in quality of life Moderate Less edema, better tolerability
Disease-oriented evidence
Effective control of blood  
pressure
 
Clear
 
Combination more effective than 
monotherapy
Economic evidence
Cost effectiveness as 
antihypertensive therapy
 
Limited
 
No studies to show the long term 
efficacy for lowering blood pressure and 
decreasing morbidity or mortality in spite 
of higher cost of the fixed combinationCore Evidence 2009:4 
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Scope, aims, and objectives
This article discusses the place of combination therapy in 
arterial hypertension (HTN) and concentrates on the potential 
advantage of Exforge® (Novartis), the first commercially 
available combination of a dihydropyridine calcium channel 
blocker (CCB) (amlodipine) and an angiotensin II receptor 
blocker (ARB) (valsartan). These are two of the most commonly 
prescribed antihypertensive drugs in their classes. Their 
combination aims to secure better control of blood pressure 
(BP) along with simultaneous cardiovascular and renal risk 
reduction and few side effects. The scope of this article is in the 
area of human hypertension and its treatment, with particular 
focus on amlodipine, valsartan, and their combination.
Methods
An extensive literature search on amlodipine/valsartan was 
conducted as follows.
Peer reviewed articles and abstracts (English-language 
only) were identified from Medline, EMBASE, BIOSIS, 
the National Institute for Health and Clinical Excellence 
(NICE), and the York University Centre for Reviews and 
Dissemination Database (http://www.crd.york.ac.uk/
crdweb/) using the terms “antihypertensive combination, 
amlodipine, valsartan, CCB, and ARB.”
PubMed was used for the terms “amlodipine and 
valsartan” with the search limits “clinical trial, meta-analysis, 
practice guideline, randomized controlled trial, hypertension 
treatment”, and English language only. Forty-nine records 
were found, of which 11 were reviews on the topic. Only 
15 of the records appeared relevant to the combination of 
both drugs. The search also produced records of trials that 
compared amlodipine and valsartan; they were included in 
this review to substantiate the evidence of the efficacy and 
tolerability of each individual drug.
A search on the site of the European Medicines Agency 
(EMEA), (www.emea.europa.eu), was also done with 
Exforge as the topic searched. EMBASE and BIOSIS 
were also consulted with the same search keywords, but 
the records that were identified were already found in the 
PubMed results. For NICE, no records were found. From 
the York University Centre for Reviews and Dissemination 
Databases, four records were identified, but for the purpose 
of the present article, none were judged relevant. The results 
of the literature search are shown in Table 1.
The main aims of all the studies selected were the efficacy 
of antihypertensive effect and tolerability.
Most of these articles were the results of prospective, 
randomized, either double-blind or open-label multicenter 
studies, placebo-or active-treatment controlled, with samples 
including men and women of a mean age around 60 years. 
Additional references were obtained from the authors’ files.
Disease overview
Hypertension is a well-known risk factor for cardiovascular 
disease, affecting more than 1 billion people worldwide. 
Recently, Lawes et al1 summarized the worldwide burden 
of disease attributable to high BP and found that 7.6 million 
premature deaths and 92 million disability-adjusted life years 
were attributed to high BP. Half of strokes and ischemic heart 
disease worldwide were attributable to high BP. About half 
this burden was in people with HTN, the remainder was in 
those with lesser degrees of high BP. The prevalence of HTN 
varies according to the country, with a range between 5% in 
rural India to 70% in Poland.2
The economic impact of HTN is enormous, representing 
US$24 billion in the US in 1995, and more than one-third 
of that cost is due to drug treatment.3 Further, Goetzel et al4 
suggest that HTN carries a high per-employee cost, even 
higher than that of heart disease, depression, or arthritis.
Despite the effort to increase the awareness and treatment 
of HTN, recent data for the US show that only 39% of patients 
have their BP adequately controlled.5 In Europe, BP control 
was achieved in only 12% of Polish hypertensives and up 
to 36% of Spanish hypertensives.6 These statistics show the 
need to change the landscape of BP management.
Current therapy options
The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of HTN7 
Table  Evidence base included in the review
Category Number of records
Full papers Abstracts
initial search 49 12
  records excluded 34
  records included 15 1
Additional studies identified 46 1
Total records included 61
Level 1 clinical evidence 10
(systematic review, meta 
analysis)
Level 2 clinical evidence (rCT) 37
Level  3 clinical evidence 11 2
trials other than rCT
Economic evidence 3
Notes: For definitions of levels of evidence, see Core Evidence website (http://www.
dovepress.com/core-evidence-journal).
Abbreviation: rCT, randomized controlled trial.Core Evidence 2009:4 
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recommends a BP treatment goal of 140/90 mmHg for most 
patients and 130/80 mmHg for those with diabetes mellitus 
or chronic kidney disease. These targets conform to the more 
recent European guidelines.8 These target BP goals should 
reduce the long-term risk of cardiovascular disease and death. 
In most hypertensive subjects, optimal control of the BP will 
depend on effective and trouble-free medication.
Choosing the appropriate medications for individual 
patients and adherence to these regimens are the key 
factors for successful treatment of HTN. Diuretics remain 
an important drug class with a large amount of evidence 
for their efficacy. They are also inexpensive, but they have 
potential adverse metabolic side effects. When used alone, 
they are often stopped during the first year of their use, with 
a one-year persistence rate of only 34%.9
Medications that act on the renin-angiotensin-aldosterone 
system (RAAS) are now frequently prescribed because they 
block important renal mechanisms that play a crucial role 
in salt and volume homeostasis, and because of additional 
extrarenal actions. They also reduce major cardiovascular 
events in high-risk patients.10,11
For their part, calcium antagonists have regained popularity 
in spite of worries about short-acting calcium antagonists.12 
They have been used in many recent hypertension treatment 
trials (eg, ALLHAT, VALUE, ASCOT) and may have utility 
because of their neutral metabolic effects and also potential 
antiatherosclerotic properties.
The current market share in the US for angiotensin-
converting enzyme (ACE) inhibitors and angiotensin-
receptor blockers (ARBs) is near 50%, while that of calcium 
blockers is 20%.13 These are thus major drug classes for the 
treatment of hypertension.
Unmet needs
Of the unmet medical needs in the management of HTN, there 
is strong evidence to support simpler treatment regimens that 
effectively control BP and that are still used by patients in 
the long term because they are well tolerated.
Major trials, such as LIFE, ASCOT, and VALUE, have 
shown that up to 80% of hypertensive patients need more 
than one antihypertensive agent to get to and maintain their 
BP goal. In the Hypertension Optimal Treatment study 
(HOT), an average of 3.3 drugs were required to attain a 
diastolic BP goal of 80 mmHg.14 Furthermore, the JNC7 
recommendations state that “when BP is more than 20 mmHg 
above systolic goal or above 10 mmHg diastolic goal, 
consideration should be given to initiate with 2 drugs, either 
as separate prescriptions or in fixed-dose combinations”.7
For those with reduced kidney function, the number of 
medications needed to control BP rises as the glomerular 
filtration rate (GFR) falls15 (Figure 1). Combination therapy 
thus appears to be an attractive option for the 10% of 
hypertensives who have stage II hypertension or more and 
for those with chronic kidney disease and HTN.
Combination therapy could improve adherence to therapy 
(“compliance”), due to reduction of the daily pill intake.16 
Better adherence to HTN therapy could enhance individual 
and population-level BP control. Some authors consider 
that improvement of treatment compliance could yield the 
greatest gain both in cost effectiveness and efficiency.17
In addition, BP has multiple regulatory pathways, including 
the sympathetic nervous system, RAAS, and total body sodium. 
Combination therapy relies on efficient and complementary 
blockade of more than one of these, by separate and different 
agents, and without resorting to a high dose of either. This was 
shown by Andreadis et al18 who noted that low-dose ARBs and 
CCBs had comparable effects in patients with grade I and II 
HTN. In patients who were not controlled by low-dose mono-
therapy, low-dose combination therapy using agents blocking 
different BP control pathways was more effective than was 
high-dose monotherapy. Such a complementary advantage 
was also reported by Stergiou et al19 who showed that adding 
amlodipine or chlorthalidone to valsartan was more effective 
than add-on therapy with benazepril.
Additional reasons for inadequate BP control could derive 
from a suboptimal approach by physicians.20 Yet the role 
of BP reduction in cardiovascular risk prevention is quite 
clear, and a greater reduction in BP yields greater reduction 
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SBP-138-144
*
SBP-128-136
SBP-136-142
SBP-138-141
SBP-140-142
N
u
m
b
e
r
 
o
f
 
B
P
 
m
e
d
i
c
a
t
i
o
n
s
90–99 80–89 60–69 50–59 40–49
4.5
3.5
2.5
1.5
0.5
Figure  relationship between level of baseline GFr and number of antihypertensive 
medications needed to achieve BP goal. SBP reflects BP ranges in the studies reviewed. 
Copyright © 2005.   Adapted from studies reviewed in 2004 Disease Outcomes Quality 
initiative-Blood Pressure (DOQi – BP) guidelines. Black squares are diabetic studies; 
black diamonds are nondiabetic studies. This figure is reprinted by permission of the 
American Society of Nephrology and by Dr George Bakris, from NephSAP 4:101, 
2005, the Nephrology Self-Assessment Program published by the American Society 
of Nephrology. 
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in risk.21,22 Getting to goal BP may require more than one 
antihypertensive drug.
Over the years, several combinations with fixed-dose 
drugs have been developed and shown to be effective. Some 
have had specific indications based on hemodynamic and 
metabolic criteria.23 These have included:
1.  Thiazide diuretics and either beta blocker, ACE inhibitor, 
or ARB, for uncomplicated HTN, for heart failure, or left 
ventricular hypertrophy, respectively.
2.  CCB and betablocker for HTN and coronary artery dis-
ease, or CCB and ACE inhibitor for HTN with kidney 
disease or with high cardiovascular risk.
The side effects of diuretics, beta blockers, and ACE 
inhibitors may limit the benefit of combinations using these 
drugs and also decrease patient adherence to treatment.
The combination of amlodipine/valsartan has been 
developed to try to improve efficacy and tolerability and thus 
deliver the promise of better treatment. Both amlodipine and 
valsartan have a favorable side effect profile, so their combi-
nation is attractive. Both drugs act on different mechanisms 
of hypertension and thus could be complementary in the 
benefit that they offer.
Pharmacodynamic profile
The CCB is effective in low-renin HTN and the ARB in 
high-renin HTN, thus combining both classes could improve 
the success of treatment. Both drugs have generally neutral 
effects on metabolic parameters such as blood lipid levels 
and insulin sensitivity, although plasma norepinephrine 
levels are increased with amlodipine therapy. This effect is 
not attenuated when combined therapy is used.24
Amlodipine
Amlodipine is a third generation CCB that acts on specific 
high-affinity binding sites in the L-type calcium channel 
complex of vascular smooth muscle cells. This causes vaso-
dilatation of arteries and arterioles by reducing the influx of 
calcium into vascular smooth muscle. Calcium channels play 
important roles in cardiac contractility and electrophysiology 
but much higher concentrations of amlodipine are needed 
in vitro to influence those functions.25 Its protein binding 
and elimination kinetics help to explain its long duration 
of action. Amlodipine produces a gradual onset of action 
and a prolonged effect that enables once-daily dosing. This 
explains the high trough-to-peak ratio of the antihypertensive 
effect and reduced variability of BP with once-daily admin-
istration. The vasodilatation can induce flushing, headache, 
and ankle edema.
Experimental data indicate that amlodipine has the 
potential to produce an antiatherosclerotic effect in humans, 
in part due to antioxidant effect or its endothelin antago-
nistic properties. Amlodipine can improve endothelium 
dysfunction, thanks to reduction of calcium influx, and, by 
its R-enantiomer, facilitate the action of nitric oxide or its 
production. In kidney transplant patients, amlodipine can also 
increase the glomerular filtration rate and renal blood flow, 
and decrease plasma uric acid concentration.7
valsartan
Valsartan is a specific blocker of the binding of angiotensin II 
to the AT1 receptor, blocking the vasoconstrictor effect and 
the adrenal aldosterone secretion induced by this peptide. 
Valsartan does not significantly increase bradykinin 
concentrations, in contrast to ACE inhibitors. It reduces BP 
without increasing the heart rate. It has a 24-hour effect on 
BP control due to blockade of the AT1 receptor, but there may 
be an increase in angiotensin II concentration acting on AT2 
receptors, with consequent vasodilatation. In the kidneys, 
especially at the renal tubular level, the stimulation of AT2 
could mediate natriuresis which could also contribute to the 
antihypertensive effect.26,27 Stopping valsartan intake is not 
associated with rebound of the BP level.
Pharmacokinetic profile
Limited data are available on the pharmacokinetic proper-
ties of fixed-dose combinations of amlodipine/valsartan. No 
drug interaction studies have been conducted with fixed-dose 
combinations and other drugs.
Amlodipine
When orally absorbed, peak plasma concentrations of 
amlodipine are reached in 6–8 hours and its bioavailability 
is 64–80%. It has an inherently long half-life of between 30 
and 50 hours with gradual onset of action and a prolonged 
effect, which is useful for once-daily dosing, and no rebound 
of HTN when the drug is abruptly stopped. It has 98% plasma 
protein binding and is extensively metabolized in the liver 
to inactive metabolites.28,29
Amlodipine can interfere with the metabolism of 
some drugs through the enzyme CYP3A, because this 
enzyme constitutes the pathway of its catabolism. Any 
substance that induces or inhibits CYP3A could affect 
amlodipine concentration, and amlodipine could also modify 
the concentration of the coadministered drug.30 An increase 
in cyclosporin concentrations may occur but is of limited 
clinical significance.Core Evidence 2009:4 
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valsartan
Peak plasma concentrations of valsartan are reached 3 hours 
after oral administration. Its bioavailability is 23% and this 
is not influenced by food. Its half-life is 6 hours and its 
plasma protein binding is over 95%. Like amlodipine, it is 
metabolized by the liver. Valsartan is eliminated mainly as 
unchanged drug in the faeces (83% of the dose) and urine 
(13% of a dose). It is not metabolized by the CYP system 
and thus has little interference with other drugs. In hepatic 
failure its concentration is increased. In renal impairment, 
its dosage does not need modification and it is not removed 
by dialysis. Its main contraindication is pregnancy, because 
antagonists of the RAAS may be teratogens. Valsartan can 
worsen kidney function in patients with bilateral renal artery 
stenosis, and in this condition of use requires surveillance of 
serum potassium and creatinine.28,29
Clinical evidence with amlodipine
The long-acting third-generation dihydropyridine calcium 
antagonist amlodipine is one of the most commonly used 
antihypertensive agents, and is approved for the treatment 
of HTN and angina at doses from 2.5 to 10 mg/day. It has 
no effects on lipids or insulin sensitivity, but it can increase 
plasma norepinephrine levels. It has been shown to activate 
the sympathetic system during the day and to decrease the 
parasympathetic activity during the night.31
Amlodipine has been studied in patients with coronary 
artery disease and shows benefit compared with placebo 
or enalapril in terms of cardiovascular events, with a trend 
towards an antiatherosclerotic effect even in normotensive 
patients who have coronary heart disease.32 It may exert a 
preferential effect in lowering central aortic pressures.33
Amlodipine is not recommended as first-line treatment in 
hypertensives with proteinuric renal disease because it may 
aggravate proteinuria.34,35 It is possible that this is related to 
an increase in glomerular capillary pressure that may occur in 
patients taking amlodipine.36 Compared with RAAS blockers, 
amlodipine use in proteinuric kidney disease was not as 
useful in preventing renal disease progression.37,38
Clinical evidence with valsartan
Valsartan is an ARB that has been marketed for HTN since 
1996. It is available in the US at 80–320 mg/day and in 
Europe at 80–160 mg/day. Valsartan is approved for the 
treatment of HTN, for congestive heart failure, and also for 
postmyocardial infarction patients in some countries.
Valsartan has also been described as having antiinflammatory 
properties reducing the high sensitivity C-reactive protein 
level, as shown in the Val-MARC trial. However, this 
antiinflammatory effect has not been confirmed in the VIVALDI 
study comparing valsartan with telmisartan.39,40
Comparisons of amlodipine  
and valsartan
Although not the focus of this review, some comparisons 
of amlodipine and valsartan are relevant to the discussion of 
the combination of both drugs.
Wogen et al41 compared patient adherence with amlodipine, 
lisinopril, or valsartan therapy in people treated for HTN. In 
a usual-care setting, patients receiving valsartan rather than 
lisinopril or amlodipine appear to be more compliant with 
treatment, due to less subjective side effects. Moreover, 
Elliott et al42 reported that, probably for the same reasons, 
the risk of discontinuation of four antihypertensive drugs 
(hydrochlorothiazide, amlodipine, lisinopril, and valsartan) 
was different. The lowest risk of discontinuation was seen with 
the ARB, followed by the ACE inhibitor, then the CCB, with 
the highest discontinuation rate being noted with the thiazide. 
This could be explained by a superior tolerance profile of ARB 
compared with the other antihypertensive classes.
For cardiovascular protection, an action on oxidative stress 
may be beneficial. Dihydropyridine CCBs have antioxidant 
and antiinflammatory effects that may be independent of their 
BP-lowering action and that yield synergistic vasoprotective 
activity with RAAS blockers.43 The reduction of oxidative 
stress and plasma methyl arginine, an endogenous inhibitor 
of nitric oxide synthase, has also been noted in patients 
with chronic renal failure treated with either amlodipine or 
valsartan.44 However, valsartan seems to be more effective 
than amlodipine in restoring endothelial function and 
decreasing oxidative stress in essential HTN.45
Clinical evidence with amlodipine/
valsartan combination
Exforge® is a fixed-dose combination of amlodipine, as the 
besilate salt, and valsartan, in the form of film-coated tablets. 
Fixed-dose combinations of amlodipine (5 or 10 mg) and 
valsartan (160 or 320 mg) have been available in the US 
and several countries in Europe since September 2007 for 
once-daily oral administration in patients with HTN who 
have not had an adequate response to amlodipine (or another 
dihydropyridine CCB) or valsartan (or another ARB alone) 
as monotherapy. Exforge® was recently approved by the 
FDA as initial or first-line therapy in patients likely to need 
multiple drugs to achieve their BP goals.Core Evidence 2009:4 
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There have been only a few studies testing this 
combination of the two drugs. The addition of valsartan 
80 mg/day to amlodipine 5 mg/day in patients not controlled 
with amlodipine 5 mg alone has been shown to improve 
exercise performance assessed by measurements of cardiac 
output and total peripheral resistance at rest and at peak 
exercise.46 As noted above, in hypertensives not controlled 
with valsartan as monotherapy, a combination of amlodipine 
and valsartan has been shown to be well-tolerated, safe, and 
effective.19 Combination amlodipine/valsartan was very 
effective in lowering BP in patients in whom monotherapy 
with various other antihypertensives was incompletely 
effective.47 In this study, a variety of drugs were used at base-
line as monotherapy before the use of amlodipine/valsartan. 
Poldermans et al48 showed that amlodipine/valsartan com-
bination therapy was as effective in patients with stage II 
hypertension as lisinopril/hydrochlorothiazide combination 
therapy.
While several trials have been designed to test the 
antihypertensive efficacy of this combination, very few 
studies have been devoted to analyze its potential benefit in 
terms of cardiovascular or renal protection. The particular 
case of atrial fibrillation was tested by Fogari et al49 who 
showed that amlodipine/valsartan combination therapy was 
better than atenolol/amlodipine in preventing recurrent atrial 
fibrillation in hypertensive diabetics, although comparisons 
with an ACE inhibitor and a CCB or a diuretic would be more 
appropriate comparators in this patient population.
Currently, no information on albuminuria is available for 
the amlodipine/valsartan combination. Nonetheless, Fogari 
et al50 showed that the amlodipine/telmisartan combination 
has been very useful in decreasing urinary albumin excretion 
in hypertensive diabetic patients with microalbuminuria. The 
clinical development program for amlodipine/valsartan fixed 
combination products has included bioequivalence studies 
and phase III clinical efficacy/safety studies, including 
placebo- and active-controlled studies to justify proposed 
dosages. All of these studies showed efficacy in all grades of 
HTN, as well as efficacy in nonresponders to monotherapy 
or to previous combination therapy (Table 2).
To date, some clinical trials with combinations of both 
drugs have been published, with a focus on BP control but 
Table  randomized trials with amlodipine/valsartan combination in hypertension
Trial Design Treatment Patients
Efficacy51,52 EMEA study 
2201 + 2307
Multicenter, double-blind,  
randomized, placebo-controlled, 
parallel group
8 weeks of amlodipine 2.5, 5 mg; 
valsartan 40, 80, 160, and  
320 mg, all possible combina-
tions and placebo
1911 patients with mild-to-moderate 
diastolic HTN
Efficacy51,52 EMEA study 
2201 + 2307
Multicenter, double-blind,  
randomized, active-controlled, 
parallel group
8 weeks of amlodipine/valsartan 
(5/160 mg and 10/160 mg) 
compared with valsartan 160 mg
1250 patients with mild-to-moderate 
diastolic HTN
Efficacy and safety in 
severe HTN48 EMEA 
study 2308
Multicenter, double-blind,  
randomized, active-controlled, 
parallel group
8 weeks of amlodipine/valsartan 
(5/160 mg and 10/160 mg) 
compared with valsartan 160 mg
947 adults with mild-to-moderate 
HTN uncontrolled by valsartan 
160 mg
Efficacy and safety 
EX-FAST47 EMEA study 
2401 mild-to-moderate 
HTN
Multicenter, double-blind,  
randomized, active-controlled, 
parallel group
16 weeks of amlodipine 5 or 
10 mg/ valsartan 160 mg compared 
with previous monotherapy
894 patients receiving the 
combination (443 with amlodipine 
5 mg and 451 with amlodipine 
10 mg) with mild-to-moderate HTN 
uncontrolled by monotherapy
Efficacy and safety 
EX-EFFeCTS study53 
EMEA study 2403
Multicenter, double-blind,  
randomized, active-controlled, 
parallel group
8 weeks amlodipine/valsartan 
vs amlodipine monotherapy in 
systolic stage ii HTN
646 patients with stage ii and iii HTN 
receiving either the amlodipine 5 or 
10 mg/valsartan 160 mg combination 
(n = 322) or amlodipine monotherapy 
5 or 10 mg (n = 324)
Nonresponder study 
ExPress-C trial54
Open-label, simple arm 5 weeks amlodipine/valsartan 
10/160 mg compared with 
ramipril 5 mg/felodipine 5 mg
105 patients with stage ii HTN 
uncontrolled by ramipril/felodipine 
after 5 weeks
Nonresponder study55 
EXPrESS-M trial
Open-label, simple arm 8 weeks amlodipine/valsartan 
compared with amlodipine or 
felodipine monotherapy
181 patients stage ii HTN 
uncontrolled by CCB monotherapy
Abbreviations: CCB, calcium channel blocker; EMEA, European Medicines Agency; HTN, hypertension.Core Evidence 2009:4 
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without using home or ABPM, and only one study has been 
published on systolic HTN.53 Several studies have shown 
the efficacy of each component drug in reducing BP and 
cardiovascular events, as reviewed above.
Published randomized studies
1.  Combination therapy with amlodipine/valsartan has been 
compared with that of amlodipine or valsartan monotherapy 
in two large randomized double-blind, placebo-controlled 
studies and their subgroup analyses.51,52 These studies 
included 3161 patients with mild-to-moderate HTN. The 
primary efficacy endpoint was the change from baseline 
in mean sitting diastolic (D) BP at the end of the 8-week 
study period. Secondary endpoints were the percentage of 
patients achieving a DBP  90 mmHg or a 10 reduction 
from baseline, and change of mean systolic (S) BP.
  The efficacy of the combination was better than either mono-
therapy at the same dose. More than 80% of patients treated 
with amlodipine/valsartan 5/80 mg, 5/160 mg, or 5/320 mg 
met the criteria for response. This was also the case when 
the amlodipine dose in the combination was 10 mg.
    The same group51 showed that ∼50% of the patients 
treated with the combination of amlodipine 10 mg and 
valsartan 320 mg achieved the BP goal of 140/90 mmHg 
at 2 weeks. The combination therapy was associated 
with greater reductions in BP than each separate 
monotherapy or placebo across all patient subgroups, 
including those aged 65 years, black patients, and those 
with stage II HTN.52
2.  A large, randomized, double-blind, phase IIIb-IV trial 
in almost 900 patients evaluated a direct switch to 
amlodipine/valsartan 5/160 mg or 10/160 mg once daily in 
patients whose BP was previously uncontrolled by mono-
therapy with various antihypertensive agents.47 Patients 
whose BP was uncontrolled with the combination after 8–
12 weeks could receive diuretics. BP control was achieved 
in 76% and 71 % of patients after 8 weeks of combination 
with amlodipine/valsartan 10/160 mg or 5/160 mg, respec-
tively. For both dosage regimens, the magnitude of SBP 
reductions was similar regardless of the class of antihy-
pertensive drug used prior to randomization.
3.  Brachmann et al55 recently showed that the addition of 
an ARB to CCB-based antihypertensive therapy may be 
associated with enhanced efficacy and reduced risk of 
adverse events. In this 8-week, open-label, single-arm trial, 
the efficacy and tolerability of the combination of amlodipine 
and valsartan was evaluated in patients not responding 
adequately to treatment with amlodipine or felodipine 
alone. Patients aged 18 years with moderate essential 
hypertension (defined as mean sitting SBP  160 and 
180 mmHg) were treated for 4 weeks with amlodipine 
5 mg or felodipine 5 mg once daily. At week 4, patients 
not adequately responding were treated for an additional 
4 weeks with a fixed dose combination of once-daily 
amlodipine/valsartan 5/160 mg. Of 214 patients treated 
for 4 weeks with amlodipine 5 mg or felodipine 5 mg, 
181 failed to achieve mean sitting SBP 140 mmHg. 
These 181 nonresponders were treated for an additional 
4 weeks with amlodipine/valsartan 5/160 mg: over half of 
them achieved target BP level ( 140/90 mmHg).
4.  Poldermans et al48 showed that better BP control was 
achieved with the combination of amlodipine/valsartan 
5/160 mg or 10/160 mg than with the combination of 
lisinopril 10 or 20 mg and hydrochlorothiazide 12.5 
or 25 mg in adult patients with stage II HTN. Mean sitting 
SBP/DBP was reduced by 36/29 mmHg and 32/28 mmHg, 
respectively, but this was not statistically significant. 
Subgroup analyses showed that both combination 
regimens reduced BP from baseline in two important 
patient groups; those aged 65 years at baseline and those 
with SBP  180 mmHg at baseline (ie, stage III HTN).
5.  Trenkwalder et al54 tested the efficacy of treatment with 
the combination of ramipril 5 mg and felodipine 5 mg. 
In patients who were resistant to this combination, they 
evaluated the efficacy of switching to amlodipine/valsartan 
10/160 mg. The amlodipine/valsartan combination led to 
a significant additional BP reduction, of 15 mmHg for 
SBP and 7 mmHg for DBP (P  0.001). Moreover, there 
was a better safety and tolerability profile for amlodipine/
valsartan compared with ramipril/felodipine.
6.  Destro et al53 assessed the efficacy and safety of 
amlodipine/valsartan versus amlodipine monotherapy 
in patients with systolic stages II and III HTN (sitting 
SBP between 160 and 200 mmHg) in a randomized, 
double-blind, 8-week trial. A total of 646 patients were 
enrolled, of whom 322 were treated with amlodipine/
valsartan 5/160 mg (group 1) and 324 were treated with 
amlodipine 5 mg for 2 weeks (group 2). For the remainder 
of the study, there was a dose increase to 10/160 mg in 
group 1 and 10 mg in group 2. At week 4, if patients 
were not controlled (SBP  130 mmHg), open label 
hydrochlorothiazide 12.5 mg could be added.
At week 4, the change from baseline SBP was 
significantly greater with amlodipine/valsartan compared 
with amlodipine monotherapy (decrease in SBP of 30 mmHg 
versus 24 mmHg; P  0.0001). By the end of the study, Core Evidence 2009:4 
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SBP was reduced from a baseline of 171 to 137 mmHg in 
the amlodipine/valsartan arm compared with 145 mmHg in 
the amlodipine treatment arm (P  0.0001). The difference 
in response was similar whatever the subgroup analysis 
(ie, the elderly, those with severe HTN, obese patients, or 
those with diabetes mellitus).
Tolerability and safety
The most frequently reported adverse events with amlodipine/ 
valsartan were ankle edema, headache, nasopharyngitis, 
upper respiratory tract infection, and dizziness. The aggregate 
frequency of adverse events was not different for amlodipine 
monotherapy (46%) as compared with amlodipine/valsartan 
combination (44%) but was higher than that reported for 
valsartan alone (40%).51 The frequency of ankle edema 
was greatest with amlodipine alone (9%), followed by the 
combination (5%), and was least common with valsartan 
monotherapy (2%). For the placebo group, the frequency of 
edema was 3%.51
Ankle edema was studied in detail by Fogari et al56 
Objective ankle foot volume and pretibial subcutaneous 
tissue pressure were masked endpoints after 6 weeks 
of amlodipine monotherapy or amlodipine/valsartan 
combination therapy. Ankle edema was most common in 
those on amlodipine monotherapy, least common in those 
on valsartan monotherapy, and of intermediate frequency 
in those on combination therapy. The ankle edema with 
CCB may be due to high capillary hydrostatic pressure from 
precapillary vasodilatation. Several drug classes have relevant 
venodilating potential, including ACE inhibitors, ARBs, and 
nitrates. The use of valsartan, which has a mixed vasodilating 
effect on arteriolar and venular sites, may decrease the post-
capillary pressure thereby normalizing transcapillary pressure 
and reducing edema. Another mechanism explaining a less 
frequent development of edema with the combination of 
amlodipine and valsartan could be the natriuretic effect of 
angiotensin blockade.
In the study published by Poldermans et al48 most of the 
adverse events were not considered to be related to the study 
drugs. Mild-to-moderate adverse events were reported in 41% 
of patients treated with amlodipine/valsartan and 32% in 
the group treated with lisinopril/hydrochlorothiazide. Headache 
(11%) and peripheral edema (8%) were reported mainly in 
the amlodipine/valsartan group whereas diarrhea and phar-
yngitis occurred mainly in the lisinopril/hydrochlorothiazide 
group (6% for both). Cough occurred in 3% of those on 
lisinopril, but in fewer than 2% of those in the amlodipine/
valsartan combination.
Economic evidence
In HTN without any other associated cardiovascular risk 
factor, the treatment cost increases as the target for HTN 
is lowered but this effect is attenuated when the population 
tested is older or has higher cardiovascular risk. Cost effec-
tiveness may be better for older compared to younger people 
and for higher starting levels of BP. Cost effectiveness of 
treatment for HTN is also improved in secondary prevention 
or in the presence of diabetes.57
The large majority of trials in the treatment of HTN have 
shown that the benefit from the treatment correlates with 
the decrease in BP. Recently some trials have suggested 
a benefit in addition to the BP decrease when using CCB 
and/or a blocker of the RAAS such as was observed in the 
LIFE or ASCOT trials.58,59 However, the combination of 
two blockers of the RAAS (ie, ACE inhibitor and ARB) has 
not demonstrated such benefit. In the VALIANT study, the 
combination of valsartan and captopril increased the rate of 
adverse events.60 Similarly, in the Valsartan Heart Failure 
Trial (Val-HeFT), the combination of valsartan and ACE 
inhibitors or beta blocker was associated with a higher rate of 
adverse events.61 In the ONTARGET trial, the combination 
of ramipril and telmisartan conferred no additional benefit 
compared with monotherapy in high cardiovascular risk 
populations.11 Considering absolute cost, paying for 
amlodipine and valsartan separately is cheaper, as shown in 
Table 3. However, the problem of compliance is inversely 
linked to the number of pills to be taken, which may cancel 
that small cost advantage.16
Patient group/population
For the amlodipine/valsartan combination, the population 
who may benefit from its use are those patients with stage II 
or III HTN and those who have not sufficiently responded to 
Table  Average wholesale price (AwP) for Exforge® and its separate 
components
Drug AWP for 0 days ($US)
Amlodipine 5 mg 10.34
Amlodipine 10 mg 14.19
valsartan 160 mg 58.56
valsartan 320 mg 74.09
Exforge 5/160 mg 85.86
Exforge 5/320 mg 108.91
Exforge 10/160 mg 97.39
Exforge 10/320 mg 123.63
Notes:  The AwP is a prescription drugs term referring to the average price at which 
wholesalers sell drugs to physicians, pharmacies, and other customers.Core Evidence 2009:4 
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an antihypertensive monotherapy. An additional population 
of interest is those with chronic kidney disease, especially 
when the estimated GFR is less than 60 mL/min/1.73 m3.
No specific drug interaction studies have been conducted 
with this combination, but interaction of the individual single 
agents with other drugs exists and should be kept in mind 
(see above).
In April 2008, the EMEA published information about the 
avoidance of this drug combination throughout pregnancy. 
Since the fourth of December 2007, the FDA has appoved 
the use of valsartan for treating children with HTN, so 
amlodipine/valsartan could now be used in patients under 
18 years of age but not in patients allergic to amlodipine or 
other medicines in the dihydropyridine class or with allergy 
to valsartan.
Regarding safety, it should be kept in mind that this 
combination includes a blocker of the action of angiotensin II. 
Thus, in all clinical situations such as fever, dehydration, or 
diarrhea, in which the renal blood blow must autoregulate 
to avoid renal insufficiency, the ARB must be stopped and 
amlodipine alone continued if the patient still requires 
antihypertensive therapy. Potassium and creatinine should 
be monitored in those with moderate renal impairment. 
Moreover, in therapeutic conditions that predispose to 
hyperkalemia (eg, use of NSAIDs, spironolactone, or ACE 
inhibitors, as well as acute or chronic renal insufficiency), 
the presence of the ARB valsartan could mean that the 
combination may need to be stopped. Caution is advised 
when prescribing fixed-dose amlodipine/valsartan to patients 
with hepatic impairment, or biliary obstruction, or when 
increasing the dosage of the combination in elderly patients. 
Bilateral renal artery stenosis is another contraindication for 
the use of this combination.
Dosage, administration,  
and formulation
In the US, Exforge® is available as film-coated tablets of 
amlodipine 5 and 10 mg and valsartan 160 and 320 mg, 
to be administered once daily, taken with water, with or 
without food. Although a direct switch from monotherapy 
to the fixed dose may be appropriate for some patients, 
individual dose titration with amlodipine and valsartan is 
generally recommended before changing to a fixed-dose 
combination.28
Clinical value
As reviewed, this combination is effective in terms of 
reduction in BP. HTN is an important risk factor for 
cardiovascular complications and its management still needs 
improvement. The development of new strategies to improve 
the BP control is welcome. The development of efficient and 
safe combination therapy is one of these strategies as many 
patients with HTN need at least two antihypertensive agents 
to achieve BP control. Exforge is a new drug combination 
associating two well-tested antihypertensive products: the 
CCB amlodipine and the ARB valsartan. The amlodipine/
valsartan combination is an association with potential 
advantages in cardiovascular protection.
Clinical trials are ongoing to assess the efficacy and 
safety of this combination, and it is likely that others will 
follow. Currently available data have shown that this new 
formulation is well tolerated and effective even in severe 
HTN. Its cost, however, remains high compared with 
the individual component drugs and economic studies 
quantifying the possible benefit associated with improved 
compliance would be welcome.
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